USFDA completes cGMP inspection at OneSource Specialty Pharma’s SPD facility

The United States Food and Drug Administration (USFDA) has conducted a routine current Good Manufacturing Practices (cGMP) inspection at OneSource Specialty Pharma’s Sterile Product Division (SPD) facility located at Opp. IIM, Bilekahalli, Bannerghatta Road, Bengaluru, from June 22, 2026 to June 30, 2026. The inspection has concluded with one observation. The company will respond to the observation comprehensively to FDA within the stipulated time frame.

OneSource Specialty Pharma is a multimodal specialty pharma CDMO with end-to-end capabilities across technology platforms and therapeutic modalities.